HNB
OVID icon

Huntington National Bank’s Ovid Therapeutics OVID Stock Holding History

Huntington National Bank’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$371 Buy
+213
New +$550 ﹤0.01% 2662

Other funds holding OVID

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

Huntington National Bank's OVID Position: Q2 2026 in Review

Huntington National Bank opened a new position in Ovid Therapeutics (OVID) in Q2 2026: 213 shares worth $371. The stake represents ﹤0.01% of the portfolio and ranks #2662 among its holdings.

75 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Huntington National Bank held 213 shares of Ovid Therapeutics worth $371 as of Q2 2026.
  • Ovid Therapeutics was a new Huntington National Bank position in Q2 2026.
  • Ovid Therapeutics made up ﹤0.01% of Huntington National Bank's portfolio in Q2 2026, its #2662 holding.
  • 75 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Huntington National Bank's 13F filing for Q2 2026, filed 13 Aug 2026.